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1 Table and 1 Figure 44 
Table 1: Summary of measures implemented or initiated during the preoperative period and related 45 
WHO recommendations for the prevention of SSIs* 46 
Figure 1: Surgical staff performing surgical hand rubbing before entering the operating room 47 
Courtesy of Didier Pittet.  48 
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ABSTRACT 49 
Surgical site infections (SSIs) are among the most preventable health-care-associated infections and 50 
are a substantial burden to health-care systems and service payers worldwide in terms of patient 51 
morbidity, mortality, and additional costs. SSI prevention is complex and requires the integration of 52 
a range of measures before, during, and after surgery. No international guidelines are available and 53 
inconsistencies in the interpretation of evidence and recommendations of national guidelines have 54 
been identified. Given the burden of SSIs worldwide, the numerous gaps in evidence based 55 
guidance, and the need for standardisation and a global approach, WHO decided to prioritise the 56 
development of evidence-based recommendations for the prevention of SSIs. The guidelines take 57 
into account the balance between benefits and harms, the evidence quality, cost and resource use 58 
implications, and patient values and preferences. On the basis of systematic literature reviews and 59 
expert consensus, we present 13 recommendations on preoperative preventive measures. 60 
 61 
INTRODUCTION 62 
Health-care-associated infections are avoidable infections that affect hundreds of millions of people 63 
each year worldwide. Following a systematic review of the literature and meta-analyses, WHO 64 
reported in 2010 that the prevalence of health-care-associated infections in low-income and middle-65 
income countries (LMICs) was two to 20 times higher than in high-income countries.1–3 Surgical site 66 
infection (SSI) was the most surveyed and most frequent health-care-associated infection in LMICs, 67 
affecting up to a third of patients who had surgery. The incidence of SSI is much lower in high-68 
income countries, but it is still the second most common cause of health-care-associated infection in 69 
Europe and the USA.1,4 Furthermore, data from the USA showed that up to 60% of the 70 
microorganisms isolated from infected surgical wounds have antibiotic resistance patterns.5 71 
Considering the epidemiological importance of SSIs, and the fact that these infections are largely 72 
preventable, WHO decided to prioritise the development of evidence-based recommendations for 73 
the prevention of SSIs. Many factors in the patient’s journey through surgery contribute to the risk 74 
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of SSI, and prevention is complex and requires the integration of a range of measures before, during, 75 
and after surgery. Further strong reasons to develop global guidelines on this topic include the 76 
absence of any international guidance document and inconsistencies in the interpretation of the 77 
evidence and strength of recommendations in national guidelines. We present the WHO 78 
recommendations for measures to be implemented or initiated during the preoperative period. 79 
These were elaborated according to the best available scientific evidence and expert consensus with 80 
the aim to ensure high-quality care for every patient, irrespective of the resources available. 81 
Important topics such as SSI surveillance are not mentioned in this Review because formal 82 
recommendations have not been made, but they are extensively reviewed in the WHO guidelines as 83 
cornerstones of SSI prevention. The intended audience for these recommendations is primarily the 84 
surgical team (ie, surgeons, nurses, technical support staff , anaesthetists, and any professionals 85 
directly providing surgical care), infection prevention and control professionals, policymakers, senior 86 
managers, and hospital administrators. People responsible for staff education and training are also 87 
key stakeholders and implementers. 88 
 89 
METHODS 90 
Data gathering 91 
We developed the WHO guidelines following the standard methods described in the WHO handbook 92 
for guideline development.6 We identified and formulated key research questions on priority topics 93 
for SSI prevention according to the Population, Intervention, Comparator, Outcomes process,7 on 94 
the basis of expert opinion. SSI and SSI-attributable mortality were the primary outcomes for all 95 
research questions. We did targeted systematic literature reviews and reported the results 96 
according to the PRISMA guidelines.8 97 
The quality of the studies was assessed using the Cochrane Collaboration tool to assess the risk of 98 
bias of randomised controlled trials (RCTs) and the Newcastle-Ottawa Quality Assessment Scale for 99 
cohort studies.9,10 We did meta-analyses of available studies using Review Manager version 5.3, as 100 
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appropriate. We pooled crude estimates as odds ratios (ORs) with 95% CIs using a random effects 101 
model, and used the Grading of Recommendations Assessment, Development, and Evaluation 102 
methods to assess the quality of the retrieved evidence.11,12 We graded the quality of studies as high, 103 
moderate, low, or very low. 104 
 105 
Data analysis and the development of recommendations 106 
A guidelines development group was formed to assess the available evidence, develop 107 
recommendations, and decide on their strength on the basis of the balance between benefits and 108 
harms, the evidence quality, cost and resource use implications, and user and patient values and 109 
preferences. Members of the panel were key international experts selected by taking into account 110 
geographical distribution and gender balance, and ensuring representation from various professional 111 
groups, including surgeons, nurses, infection prevention and control professionals, infectious disease 112 
specialists, researchers, and patient representatives. They rated the strength of recommendations as 113 
either strong (the expert panel was confident that the benefits of the intervention outweighed the 114 
risks) or conditional (the panel considered that the benefits of the intervention probably outweighed 115 
the risks), on the basis of the quality of the evidence and an assessment of resource implications and 116 
feasibility, as well as patients’ values and preferences. Strong recommendations are considered to 117 
be adaptable for implementation in most (if not all) situations, and patients should receive the 118 
intervention as the course of action. For conditional recommendations, a more structured decision-119 
making process should be undertaken, on the basis of stakeholder consultation and the involvement 120 
of patients and health-care professionals. The recommendations and their individual strength, and 121 
the background research questions and remarks for implementation in LMICs are presented in the 122 
table. 123 
  124 
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RECOMMENDATION 1: PERIOPERATIVE DISCONTINUATION OF IMMUNOSUPPRESSIVE AGENTS 125 
The panel suggests not to discontinue immunosuppressive medication before surgery to prevent SSI 126 
(conditional recommendation, very low quality of evidence). Immunosuppressive agents commonly 127 
used for preventing the rejection of transplanted organs or for the treatment of inflammatory 128 
diseases could lead to impaired wound healing and an increased risk of infection in patients 129 
administered these agents.14 By contrast, the discontinuation of immunosuppressive treatment 130 
could induce flares of disease activity, and long-term interruptions of therapy might induce the 131 
formation of anti-drug antibodies and subsequently decrease their effect.15 We did a systematic 132 
review and meta-analyses to assess whether the discontinuation of immunosuppressive therapy in 133 
the perioperative period is effective to prevent SSIs in patients who undergo surgery. 134 
We identified eight studies (one RCT,16 one quasi-RCT,17 and six observational studies14,18–22) com 135 
paring the perioperative discontinuation of immune-suppressive medication versus continuation. 136 
The timepoint and time interval of discontinuation of the immunosuppressive agent were very 137 
heterogeneous across studies, or not specified. Six (one RCT,16 one quasi-RCT,17 and four 138 
observational studies18–20,22) investigated methotrexate, and meta-analyses showed that the 139 
perioperative discontinuation of methotrexate might either be harmful or have no effect on SSI 140 
versus the continuation of methotrexate. The combined odds ratio (OR) was 7·75 (95% CI 1·66–141 
36·24) for the controlled trials and 0·37 (0·07–1·89) for the observational studies. Two observational 142 
studies14,21 investigated the use of anti-tumour necrosis factor (TNF). Meta-analysis showed that the 143 
perioperative discontinuation of anti-TNF might have a benefit of reducing SSI compared with its 144 
continuation (OR 0·59; 0·37–0·95). The overall quality of the evidence was rated as very low. 145 
Considering the scarce (or absent) evidence to support discontinuation of treatment (anti-TNF) and 146 
even potential harm it may cause (methotrexate) such as the risk of flare-up of the underlying 147 
disease(s) associated with the suspension of therapy, immunosuppressive medication should not be 148 
dis continued to prevent SSI. The decision to discontinue the immunosuppressive medication should 149 
be made on an individual basis and involve the prescribing physician, the patient, and the surgeon. 150 
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RECOMMENDATION 2: ENHANCED NUTRITIONAL SUPPORT 151 
The panel suggests considering the administration of oral or enteral multiple nutrient-enhanced 152 
nutritional formulas to prevent SSI in underweight patients who undergo major surgical operations 153 
(conditional recommendation, very low quality of evidence). 154 
The nutritional status of patients can lead to alterations in host immunity that can make them more 155 
susceptible to postoperative infections. Early nutritional support can improve the outcome of major 156 
surgery and decrease the incidence of infectious complications in selected malnourished or severely 157 
injured patients.23,24 Many researchers believe that nutritional interventions can reduce SSIs and 158 
associated morbidity. However, results related to the epidemiological association between incisional 159 
SSIs and malnutrition have varied, depending on the surgical subspecialties. We did a systematic 160 
review to investigate the effect of enhanced nutritional support versus standard nutrition for the 161 
prevention of SSI. 162 
We identified ten studies (eight RCTs25–32 and two observational studies33,34) comparing the use of 163 
multiple nutrient-enhanced nutritional formulas (containing any combination of arginine, glutamine, 164 
omega-3 fatty acids, and nucleotides) administered through oral and enteral routes with standard 165 
nutrition. Meta-analyses showed that a multiple nutrient-enhanced nutritional formula was 166 
associated with significantly reduced SSI incidence compared with a standard formula, both in the 167 
RCTs (combined OR 0·53; 95% CI 0·30–0·91) and the observational studies (combined OR 0·07; 0·01–168 
0·53). The quality of the evidence was rated as very low. Six studies (five RCTs32,35–38 and one 169 
observational study39) compared the use of nutritional supplements enhanced with a single nutrient 170 
(either arginine, glycine, or branched chain aminoacids) with standard nutrition. Meta-analyses 171 
showed no difference in the risk of SSI between the single nutrient-enhanced formula and standard 172 
nutrition in the RCTs (combined OR 0·61; 0·13–2·79) or the observational study (0·29; 0·06–1·39). The 173 
quality of evidence was rated as low. 174 
In conclusion, multiple nutrient-enhanced formulas can be used to prevent SSIs in adult patients 175 
undergoing major surgery. However, the use of enhanced nutrition support is expensive and requires 176 
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additional work for clinical staff , including expertise from dietitians and pharmacists. Notably, the 177 
availability of these nutrient products is low in LMICs. When considering this intervention in the 178 
context of a priority assessment approach to reduce the SSI risk, resources and product availability 179 
should be carefully assessed, particularly in settings with limited resources. 180 
 181 
RECOMMENDATION 3: PREOPERATIVE BATHING 182 
Good clinical practice requires that patients bathe or shower before surgery. The panel suggests that 183 
either a plain or antimicrobial soap can be used for this purpose (conditional recommendation, 184 
moderate quality of evidence). 185 
Preoperative whole-body bathing or showering is considered to be good clinical practice to ensure 186 
that the skin is as clean as possible before surgery and reduce the bacterial load, particularly at the 187 
site of incision. In general, an antiseptic soap is used in settings in which it is available and affordable. 188 
We did a systematic review to assess whether using an antiseptic soap for preoperative bathing is 189 
more eff ective in reducing SSIs than using plain soap. 190 
Nine studies (seven RCTs and two observational studies)40–48 examined preoperative bathing or 191 
showering with an antiseptic soap compared with plain soap. A meta-analysis showed that bathing 192 
with a soap containing the antiseptic agent chlorhexidine gluconate did not significantly reduce SSI 193 
incidence compared with bathing with plain soap (combined OR 0·92; 95% CI 0·80–1·04). The quality 194 
of evidence was rated as moderate. We also assessed whether preoperative bathing with 195 
chlorhexidine gluconate-impregnated cloths is more effective than using an antiseptic soap. Very low 196 
quality evidence from three observational studies 49–51 showed that chlorhexidine gluconate cloths 197 
were associated with a decrease in SSI compared with no bathing (OR 0·27; 0·09–0·79). In conclusion, 198 
either a plain or antiseptic soap can be used for patient preoperative bathing, but the evidence was 199 
insufficient to formulate any recommendation on the use of chlorhexidine gluconate-impregnated 200 
cloths for the purpose of reducing SSIs. 201 
 202 
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RECOMMENDATION 4 AND 5: DECOLONISATION WITH MUPIROCIN OINTMENT WITH OR WITHOUT 203 
CHLORHEXIDINE GLUCONATE BODY WASH IN NASAL CARRIERS UNDERGOING SURGERY 204 
The panel recommends that patients undergoing cardiothoracic and orthopaedic surgery who are 205 
known nasal carriers of Staphylococcus aureus, should receive perioperative intranasal applications of 206 
mupirocin 2% ointment with or without a combination of chlorhexidine gluconate body wash (strong 207 
recommendation, moderate quality of evidence). The panel suggests considering the use of the same 208 
treatment in patients with known nasal carriage of S aureus undergoing other types of surgery 209 
(conditional recommendation, moderate quality of evidence). 210 
S aureus is one of, if not the most common health-care-associated pathogen worldwide, and can have 211 
severe consequences, including postoperative wound infection, nosocomial pneumonia, catheter-212 
related bacteraemia, and increased mortality when it has meticillin resistance patterns.52–54 S aureus 213 
nasal carriage is a well defined risk factor for subsequent infection in various patient groups. Mupirocin 214 
nasal ointment (usually applied twice daily for 5 days) is an effective, safe, and fairly cheap treatment 215 
for the eradication of S aureus carriage and is generally used in combination with a whole body wash. 216 
We did a systematic literature review to establish whether decolonisation with intranasal mupirocin 217 
ointment with or without a combination of chlorhexidine gluconate soap body wash reduces 218 
prevalence of S aureus overall infection, including SSIs. 219 
Six RCTs comparing mupirocin nasal ointment with or without chlorhexidine gluconate soap body 220 
wash with placebo or no treatment were identified.55–60 Overall, a meta-analysis showed that the use 221 
of mupirocin 2% ointment with or without a combination of chlorhexidine gluconate soap body wash 222 
has a marked benefit in reducing the SSI incidence due to S aureus in patients with nasal carriage 223 
compared with placebo or no treatment (OR 0·46; 95% CI 0·31–0·69), as well as the overall incidence 224 
of health-care-associated S aureus infection (0·48; 0·32–0·71). The quality of evidence was rated as 225 
moderate. Most studies included patients undergoing cardiothoracic and orthopaedic surgery, but 226 
two trials included other types of procedures. Furthermore, a meta-regression analysis showed that 227 
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the effect on the S aureus infection prevalence did not differ between different types of surgery 228 
(p=0·986). 229 
Considering that the evidence is most solid for cardiothoracic and orthopaedic patients, and 230 
considering the feasibility and cost issues in applying this intervention to all surgical patients, the panel 231 
suggest that perioperative intranasal applications of mupirocin 2% ointment with or without a 232 
combination of chlorhexidine gluconate body wash should be done in the patient population with 233 
known S aureus nasal carriage undergoing cardiothoracic or orthopaedic surgery. This intervention 234 
could also be considered in carriers undergoing other types of surgery while taking other factors into 235 
account, such as the local prevalence of SSIs caused by S aureus and meticillin-resistant S aureus and 236 
patient-related factors (eg, past S aureus infection, known carrier status of community-acquired 237 
meticillin-resistant S aureus, and S aureus colonisation in sites other than the nose). To avoid 238 
unnecessary treatment and resistance spread, this intervention should be done only on known S 239 
aureus carriers. Therefore, these recommendations apply to facilities where screening for S aureus is 240 
feasible, and indeed, studies were done mostly in high-income countries. Notably, the studies 241 
identified as the evidence base for these recommendations did not specifically assess screening for S 242 
aureus as part of the intervention. Consequently, no recommendation can be formulated on the role 243 
of screening for S aureus carriage in this context or the surgical patient population that should undergo 244 
screening. 245 
 246 
RECOMMENDATION 6 AND 7: MECHANICAL BOWEL PREPARATION AND THE USE OF ORAL 247 
ANTIBIOTICS 248 
The panel suggests that preoperative oral antibiotics combined with mechanical bowel preparation 249 
(MBP) should be used to reduce the risk of SSI in adult patients undergoing elective colorectal surgery 250 
(conditional recommendation, moderate quality evidence), and recommends that MBP alone 251 
(without administration of oral antibiotics) should not be used (strong recommendation, moderate 252 
quality evidence). 253 
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MBP involves the preoperative administration of substances (polyethylene glycol and sodium 254 
phosphate are the most widely used) to induce voiding of the intestinal and colonic contents. It is 255 
commonly believed to reduce the risk of postoperative infectious complications by decreasing the 256 
intraluminal faecal mass, thus theoretically decreasing the bacterial load in the intestinal lumen. The 257 
administration of oral antibiotics has been combined with MBP to further decrease the intraluminal 258 
bacterial load. We did a systematic review to investigate whether preoperative MBP is effective in 259 
reducing SSI incidence in colorectal surgery. The review assessed also whether combining the 260 
preoperative administration of oral antibiotics with MBP (in addition to the standard preoperative 261 
intravenous antibiotic prophylaxis) is more effective than MBP alone.  262 
We identified 24 RCTs61–84 that compared either MBP with no MBP or the combined intervention of 263 
MBP and oral antibiotics with MBP alone in adult patients undergoing colorectal surgical procedures. 264 
A meta-analysis of 11 RCTs66,68,69,71,72,74,77,78,80–82 showed that preoperative MBP combined with oral 265 
antibiotics reduced SSI compared with MBP alone (combined OR 0·56; 95% CI 0·37–0·83). Meta-266 
analysis of 13 RCTs61–65,67,70,73,75,76,79,83,84 showed that preoperative MBP alone did not significantly 267 
affect incidence of SSIs compared with no MBP (combined OR 1·31; 95% CI: 0·99–1·72). Indeed, it was 268 
associated with a higher SSI risk, which approached statistical significance. The quality of evidence was 269 
rated as moderate for both comparisons. However, the protocols differed across trials in terms of 270 
dosage, timing of the application, fasting, and the agents used for MBP. The antibiotic regimens also 271 
differed, although amino glycosides combined with anaerobic coverage (metro nidazole or 272 
erythromycin) were the most frequently used.  273 
Possible harms associated with MBP should be considered, such as patient discomfort, electrolyte 274 
abnormalities, potentially severe dehydration at the time of anaesthesia and incision, and acute 275 
phosphate nephropathy, associated with oral sodium phosphate. Adverse effects of the oral 276 
antibiotics (eg, high risk of idiosyncratic reaction with erythromycin) and antimicrobial resistance can 277 
also occur. 278 
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In conclusion, preoperative oral antibiotics should be used in combination with MBP in adult patients 279 
undergoing elective colorectal surgery to reduce the risk of SSI. MBP should not be done alone without 280 
oral antibiotics. On the basis of the available evidence, no recommendation can be made on the 281 
preferred type of oral antibiotic, including the timing of administration and dosage, but an activity 282 
against both facultative Gram-negative and anaerobic bacteria should be guaranteed, and non-283 
absorbable antibiotics should be used preferably. Ideally, the choice of antimicrobials should be made 284 
according to local availability, updated resistance data within institutions, and the volume of surgical 285 
activity. This intervention is for preoperative use only and should not be continued postoperatively. 286 
The use of oral antibiotics in association with MBP does not replace the need for intravenous surgical 287 
antibiotic prophylaxis. 288 
 289 
RECOMMENDATION 8: HAIR REMOVAL 290 
The panel recommends that in patients undergoing any surgical procedure, hair should either not be 291 
removed or, if absolutely necessary, it should be removed only with a clipper. Shaving is strongly 292 
discouraged at all times, whether preoperatively or in the operating room (strong recommendation, 293 
moderate quality of evidence). 294 
Removal of hair from the intended site of surgical incision has traditionally been part of the routine 295 
preoperative preparation of patients. Hair is perceived to be associated with poor cleanliness and SSIs. 296 
Although hair removal might be necessary to facilitate adequate exposure and preoperative skin 297 
marking, the method used can cause microscopic trauma of the skin and increase the risk of SSIs. We 298 
did a systematic review to investigate whether the method (eg, using clippers, depilatory cream, or 299 
shaving with razors) and timing of hair removal versus no hair removal affect the incidence of SSIs. 15 300 
RCTs or quasi-RCTs85–99 comparing the effects of preoperative hair removal versus no hair removal or 301 
different methods of hair removal (shaving, clipping, and depilatory cream) were identified and 302 
several meta-analyses were done.  303 
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The three hair removal methods did not affect the incidence of SSIs compared with no hair removal. 304 
The combined ORs were 1·78 (95% CI 0·96–3·29) for shaving, 1·00 (0·06–16·34) for clipping, and 1·02 305 
(0·42–2·49) for depilatory cream. The quality of evidence was rated as moderate. However, when hair 306 
is removed, clipping significantly reduces SSIs compared with shaving (OR 0·51; 0·29–0·91). Because 307 
they have similar potential to cause microscopic skin trauma, no hair removal and clipping were 308 
combined in an additional meta-analysis, which showed that they are associated with significantly 309 
reduced prevalence of SSIs compared with shaving (combined OR 0·51; 0·34–0·78). No 310 
recommendation regarding the timing of hair removal could be formulated as only one study assessed 311 
this question with no relevant results, but the panel suggested that removal by clipping shortly before 312 
surgery is the safest approach, if required. 313 
 314 
RECOMMENDATION 9 AND 10: OPTIMAL TIMING FOR ADMINISTRATION OF SURGICAL ANTIBIOTIC 315 
PROPHYLAXIS (SAP) 316 
The panel recommends the administration of SAP before surgical incision when indicated, depending 317 
on the type of operation (strong recommendation, low quality of evidence); it should be done within 318 
the 120 min before the incision, while considering the half-life of the antibiotic (strong 319 
recommendation, moderate quality of evidence). 320 
SAP refers to the prevention of infectious complications by administering an antimicrobial agent 321 
before exposure to contamination during surgery.100 Successful SAP requires delivery of the 322 
antimicrobial agent in effective concentrations to the operative site through intravenous 323 
administration at the appropriate time. We did a systematic review to compare the effect of different 324 
timings of SAP administration on SSIs and to identify the optimal timing to prevent SSIs. 325 
We identified 13 observational studies,101–113 but no RCTs or studies in the paediatric population. We 326 
did several meta-analyses to assess different SAP timings. Low-quality evidence showed that the 327 
administration of SAP after incision was associated with a significantly higher incidence of SSI 328 
compared with administration before incision (combined OR 1·89; 95% CI 1·05–3·4). Moderate quality 329 
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evidence showed that administration earlier than 120 min before incision was associated with a 330 
significantly higher prevalence of SSI compared with administration within 120 min (combined OR 331 
5·26; 3·29–8·39). Further comparisons of administration within 60 min before incision compared with 332 
60–120 min, or within 30 min before incision compared with 30–60 min, showed no significant 333 
difference in the reduction of SSIs. However, the quality of the evidence was rated as low. 334 
On the basis of the available evidence, a more precise timing of less than 120 min before incision 335 
cannot be defined, and the widely implemented recommendation of within 60 min before incision is 336 
not supported by evidence. The half-life of the agent used, the underlying condition(s) of the individual 337 
patient (eg, bodymass index, or renal or liver function), the time needed to complete the procedure, 338 
and the protein binding of the antibiotic should be taken into account to achieve adequate serum and 339 
tissue concentrations at the surgical site at the time of incision and up to wound closure—in particular 340 
to prevent incisional SSI. For instance, administration should be closer to the incision time (<60 min 341 
before) for antibiotics with a short half-life, such as cefazolin and cefoxitin, and penicillins in general. 342 
Most available guidelines recommend a single preoperative dose; intraoperative redosing is indicated 343 
if the duration of the procedure exceeds two half-lives of the drug, or if there is excessive blood loss 344 
during the procedure. However, these concepts are not based on clinical outcome data. A specific 345 
WHO recommendation on the duration of SAP is detailed in paper 2 of this Series.13 346 
 347 
RECOMMENDATION 11: SURGICAL HAND PREPARATION 348 
The panel recommends that surgical hand preparation be done either by scrubbing with a suitable 349 
antimicrobial soap and water or using a suitable alcohol-based hand rub (ABHR) before donning sterile 350 
gloves (strong recommendation, moderate quality of evidence). 351 
Surgical hand preparation (figure) is vitally important to maintain the least possible contamination of 352 
the surgical field, especially in the case of sterile glove puncture during the procedure. Appropriate 353 
surgical hand preparation is recommended in the WHO guidelines on hand hygiene in health care 354 
issued in 2009114 and in all other existing national and international guidelines for the prevention of 355 
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SSIs. We did a systematic review to compare the effect of different techniques (ie, hand rubbing vs 356 
hand scrubbing), products (ie, different formulations of ABHRs vs plain soap vs medicated soap), and 357 
application times for the same product. 358 
We only found six studies (three RCTs115–117 and three observational studies118–120) with SSI as the 359 
primary outcome that compared hand rubbing with hand scrubbing using different products. Five 360 
studies compared ABHR with hand scrubbing with an antimicrobial soap containing either 4% 361 
povidone-iodine or 4% chlorhexidine gluconate and showed no significant difference in SSI 362 
incidence.115,117–120 Additionally, no significant difference was seen in a cluster randomised cross-over 363 
trial comparing ABHR to hand scrubbing with plain soap.116 It was not possible to do any meta-analysis 364 
of these data because the products used for hand rubbing or scrubbing were different. The overall 365 
evidence (rated as moderate quality) showed no difference between hand rubbing and hand 366 
scrubbing in reducing SSI incidence. Evidence from additional studies using the bacterial load on 367 
participants’ hands as the outcome showed that some ABHR formulations are more effective to 368 
reduce colony-forming units than scrubbing with water and antiseptic or plain soap. However, the 369 
relevance of this outcome to the risk of SSI is uncertain. Because of the use of different protocols, it 370 
was not possible to identify optimal application times for the two techniques. When selecting an 371 
ABHR, health-care facilities should procure products with proven efficacy according to international 372 
standards and position no-touch or elbow-operated dispensers in surgical scrub rooms. In LMICs in 373 
which ABHR availability might be low, WHO strongly encourages facilities to undertake the local 374 
production of an alcohol-based formulation, which has been shown to be a feasible and low-cost 375 
solution.121,122 Alternatively, antimicrobial soap, clean running water, and disposable or clean towels 376 
for each health-care worker should be available in the scrub room. 377 
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RECOMMENDATION 12: SURGICAL SITE SKIN PREPARATION 379 
The panel recommends alcohol-based antiseptic solutions that are based on chlorhexidine gluconate 380 
for surgical site skin preparation in patients undergoing surgical procedures (strong recommendation, 381 
low to moderate quality of evidence). 382 
The aim of surgical site skin preparation is to reduce the microbial load on the patient’s skin as much 383 
as possible before incision of the skin barrier. The most common agents include chlorhexidine 384 
gluconate and povidone-iodine in alcohol-based solutions, but aqueous solutions are also widely used 385 
in LMICs, particularly those containing iodophors. We did a systematic review to compare the effect 386 
of different solutions used for the prevention of SSI—ie, alcohol-based versus aqueous preparations 387 
and antiseptic agents. 388 
We identified 17 RCTs123–139 comparing antiseptic agents (povidone-iodine and chlorhexidine 389 
gluconate) in aqueous or alcohol-based solutions. Overall, a meta-analysis of 12 RCTs124,126–133,135–137 390 
showed that alcohol-based antiseptic solutions were more effective than aqueous solutions in 391 
reducing the risk of SSI (combined OR 0·60; 95% CI 0·45–0·78). More specifically, a significant 392 
reduction of the SSI risk was shown with the use of alcohol-based chlorhexidine gluconate compared 393 
with either aqueous povidone-iodine (combined OR 0·65; 0·47–0·90) or povidone-iodine in alcohol-394 
based solutions (0·58; 0·42–0·80). The quality of evidence was rated as low to moderate. 395 
Operating room staff should be trained and informed about the potential harms associated with the 396 
solutions used for surgical site preparation. Alcohol-based solutions should not be used on neonates 397 
or come into contact with mucosa or eyes, and caution should be exercised because of their 398 
flammable nature. Chlorhexidine gluconate solutions can cause skin irritation and must not be allowed 399 
to come into contact with the brain, meninges, eye, or middle ear. Notably, alcohol-based solutions 400 
might be difficult to procure and expensive in LMICs, particularly when combined with an antiseptic 401 
compound. Local production could be a more affordable and feasible option in these settings, 402 
provided that adequate quality control is in place. 403 
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RECOMMENDATION 13: ANTIMICROBIAL SKIN SEALANTS 405 
The panel suggests that antimicrobial sealants should not be used after surgical site skin preparation 406 
for the purpose of reducing SSI (conditional recommendation, very low quality of evidence). 407 
Antimicrobial skin sealants are sterile, film-forming cyanoacrylate-based sealants commonly applied 408 
as an additional antiseptic measure after using standard skin preparation on the surgical site and 409 
before skin incision. They are intended to remain in place and block the migration of flora from the 410 
surrounding skin into the surgical site by dissolving over several days postoperatively. We did a 411 
systematic review to investigate whether the use of antimicrobial skin sealants in addition to standard 412 
surgical site skin preparation is more effective in reducing the risk of SSI than standard surgical site 413 
skin preparation only. 414 
Nine studies (eight RCTs140–147 and one prospective, quasi-RCT148) were identified. Meta-analysis 415 
showed no benefit or harm for the reduction of SSI with the addition of antimicrobial sealants 416 
compared with standard surgical site skin preparation only (OR 0·69; 95% CI 0·38–1·25). Therefore—417 
also to avoid unnecessary costs—antimicrobial sealants should not be used after surgical site skin 418 
preparation for the purpose of reducing SSIs. 419 
 420 
CONCLUSION 421 
We have discussed the evidence for a broad range of preventive measures identified by an expert 422 
panel that potentially contribute to reducing the risk of SSI occurrence. For some of these, the 423 
evidence shows no benefit and the expert panel advises against the adoption of these interventions, 424 
particularly when considering resource implications or other consequences, such as antimicrobial 425 
resistance. However, the panel identified a range of key measures for SSI prevention to be 426 
implemented in the preoperative period, together with the intraoperative and postoperative periods 427 
discussed in paper 2 of this Series. Adoption should be facilitated by sound implementation strategies 428 
and practical tools. Notably, careful assessment of feasibility and cost implications in low-resource 429 
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settings is needed. 430 
 431 
Box: Search strategy and selection criteria 432 
For each population, intervention, comparator, outcomes question, we searched MEDLINE (PubMed 433 
or Ovid), Embase, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Central 434 
Register of Controlled Trials, and WHO regional medical databases, to identify relevant articles. The 435 
time limit was January, 1990, and the systematic reviews were done between December, 2013, and 436 
December, 2015. Studies in English, French, and Spanish were eligible; but some reviews were not 437 
restricted by language. A comprehensive list of search terms was used, including medical subject 438 
headings. 439 
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FIGURE 1: Surgical staff performing surgical hand rubbing before entering the operating room 870 
Courtesy of Didier Pittet. 871 
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